Aims and Scope
OncoTargets and Therapy is a peer-reviewed medical journal covering research on all aspects of oncology. The journal was established in 2008 and is published by Dove Medical Press.
Key Metrics
7
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.92
5-Year SI
5-year SI
- N/A 2-year SI
- 0.9 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q2
Oncology
SJR
- Q2 Oncology
- Q2 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.81
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Cancer
- Western blot
- Overall survival
- Lung cancer
- Assay
- Progression-free survival
- Central nervous system
- Hepatocellular carcinoma
- Irradiation
- Toxicity
- Reactive oxygen species
- Cell cycle
- Immunotherapy
- Chordoma
- Epidermal growth factor receptor
- Crizotinib
- Lung
- Colorectal cancer
- Chemotherapy
- Osteosarcoma
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2410 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2410 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in OncoTargets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Hsa_circRNA_000166 Promotes Cell Proliferation, Migration and Invasion by Regulating miR-330-5p/ELK1 in Colon Cancer [Retraction].
- 1 Apr 24
- OncoTargets and therapy
-
Full paper
Primary Epithelioid Angiosarcoma of the Jejunal Mesentery Causing Abdominal Bleeding: Case Report and Literature Review.
- 1 Apr 24
- OncoTargets and therapy
-
Full paper
Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report.
- 1 Apr 24
- OncoTargets and therapy
-
Full paper
Antitumor Effect of Triptolide in T-Cell Lymphoblastic Lymphoma by Inhibiting Cell Viability, Invasion, and Epithelial-Mesenchymal Transition via Regulating the PI3K/AKT/mTOR Pathway [Retraction].
- 1 Apr 24
- OncoTargets and therapy
-
Full paper
MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
- 1 Apr 24
- OncoTargets and therapy
-
Full paper
MicroRNA-155-3p Promotes Breast Cancer Progression Through Down-Regulating CADM1 [Retraction].
- 1 Apr 24
- OncoTargets and therapy
Scite analysis
Powered by scite_
6.5k articles received 82.3k citations see all
- 3,361 Supporting
- 77,696 Mentioning
- 373 Contrasting
Editorial notices
- 131 Retractions
- 0 Withdrawals
- 0 Corrections
- 90 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
21%
4 to 6 months
68%
7 to 9 months
8%
Above 9 months
2%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has OncoTargets and Therapy been actively publishing?
OncoTargets and Therapy has been in operation since 2008 till date.
What is the publishing frequency of OncoTargets and Therapy ?
OncoTargets and Therapy published with a Continuous publication frequency.
How many articles did OncoTargets and Therapy publish last years ?
In 2023, OncoTargets and Therapy published 138 articles.
What is the eISSN & pISSN for OncoTargets and Therapy ?
For OncoTargets and Therapy,eISSN is 1178-6930 and pISSN is1178-6930.
What is Citescore for OncoTargets and Therapy ?
Citescore for OncoTargets and Therapy is 7.
What is SNIP score for OncoTargets and Therapy ?
SNIP score for OncoTargets and Therapy is 0.81.
What is the SJR for OncoTargets and Therapy ?
SJR for OncoTargets and Therapy is Q2.
Who is the publisher of OncoTargets and Therapy ?
DOVE MEDICAL PRESS LTD is the publisher of OncoTargets and Therapy.